CRESCENT BIOPHARMA, INC.
CRESCENT BIOPHARMA, INC. (CBIO): 5 pipeline candidates · ~64 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
64.2 months
D/E 0.08 · 0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for CRESCENT BIOPHARMA, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$479.4M
Cash
$189.3M
Quarterly Burn
$8.9M
Runway
64.2 mo
Revenue
$1.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| company's product candidate uproleselan | Approved |
| cr-001 | Phase 1/Phase 2 |
| cr-002 | Phase 1/Phase 2 |
| cr-003 | Phase 1/Phase 2 |
| uproleselan | — |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
56
Total value held
$334.0M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 4,133,514 | $75.9M |
| bvf inc/il | 2,748,763 | $50.5M |
| fcpm iii services b.v. | 1,677,852 | $30.8M |
| vanguard capital management llc | 1,602,790 | $29.4M |
| balyasny asset management l.p. | 1,510,033 | $27.7M |
| tang capital management llc | 1,160,000 | $21.3M |
| logos global management lp | 482,500 | $8.9M |
| deep track capital, lp | 453,686 | $8.3M |
| perceptive advisors llc | 413,884 | $7.6M |
| nextbio capital management lp | 372,856 | $6.8M |
Showing top 10 of 56 institutional holders of CRESCENT BIOPHARMA, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in CRESCENT BIOPHARMA, INC.'s pipeline?
CRESCENT BIOPHARMA, INC. (CBIO) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CRESCENT BIOPHARMA, INC.'s lead drug candidate?
CRESCENT BIOPHARMA, INC.'s most advanced tracked candidate is company's product candidate uproleselan (Approved) for acute myeloid leukemia.
What is CRESCENT BIOPHARMA, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CRESCENT BIOPHARMA, INC. has approximately 64.2 months of cash runway.
What is CRESCENT BIOPHARMA, INC.'s market capitalization?
CRESCENT BIOPHARMA, INC.'s market capitalization is approximately $479.4M.
Who is the CEO of CRESCENT BIOPHARMA, INC.?
Mr. Joshua T. Brumm is the chief executive officer of CRESCENT BIOPHARMA, INC. (CBIO).
Get the full picture on CRESCENT BIOPHARMA, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.